Table 3 Characteristics, dosage and indications of therapeutic antibodies targeting PD-1 and PD-L1.

From: Therapeutic PD-L1 antibodies are more effective than PD-1 antibodies in blocking PD-1/PD-L1 signaling

Target

Name

Isotype

Serum half lifea

Indication

Dosage

Weekly dosageb

PD-1

Nivolumab (Opdivo®)

human IgG4κ

26.7 d

melanoma, NSCLC, renal cancer, Hodgkin lymphoma, head and neck cancer, urothelial carcinoma

3 mg/kg e.o.w.c

1.5 mg/kg

Pembrolizumab (Keytruda®)

humanized IgG4κ

25.8 d

melanoma, NSCLC, Hodgkin lymphoma, urothelial carcinoma

2 mg/kg every 3 w.d

0.67 mg/kg

PD-L1

Atezolizumab (Tecentriq®)

humanized IgG1κ

27 d

urothelial carcinoma, NSCLC

1200 mg every 3 w.

5.0 mg/kg

Avelumab (Bavencio®)

human IgG1λ

6 d

Merkel cell carcinoma

10 mg/kg e.o.w.

5.0 mg/kg

Durvalumab (Imfinzi®)

human IgG1κ

17 d

urothelial carcinoma, NSCLC

10 mg/kg e.o.w.

5.0 mg/kg

  1. aBased on data submitted to the FDA.
  2. bBased on an 80 kg body weight.
  3. cRecently approved fixed dose: 240 mg e.o.w or 480 mg every 4 weeks.
  4. dRecently approved fixed dose: 200 mg every 3 weeks.
  5. abbreviations: e.o.w., every other week; w., weeks; d, days.
Back to article page